Attempts at plaque vulnerability quantification with magnetic resonance imaging using non-contrast T1-weighted technique pilot study (AQUAMARINE Pilot Survey)
- Conditions
- Coronary artery disease
- Registration Number
- JPRN-UMIN000003567
- Lead Sponsor
- ational Cerebral and Cardiovascular Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1. Patients scheduled to undergo PCI for evaluation of plaque during the treatment period. 2. Patients who had received PCI on the index lesion in the past where further evaluation of coronary plaque is planned. 3. Patients scheduled to undergo CABG during the treatment period. 4. Patients being treated with lipid-lowering agents(statins, fibrates, probucol, niacin, anion exchange resin, EPA, dextran sulfate sodium, and ezetimibe). 5. Patients who have allergy to pitavastatin, atorvastatin , or rosuvastatin. 6. Patients on cyclosporine therapy, and patients with liver dysfunction (AST or ALT values of >=100IU) or the following diseases considered to be associated with biliary obstruction and/or impaired hepatic function: acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, hepatic carcinoma and/or icterus. 7. Pregnant or possibly pregnant women, lactating women 8. Patients with renal dysfunction (serum creatinine >=2.0 mg/dL) or dialysis patients 9. Patients who are judged by the investigator to be not eligible for enrollment in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of coronary plaque signal intensity detected by MRI.
- Secondary Outcome Measures
Name Time Method 1. Correlation between baseline characteristics and coronary plaque signal intensity detected by MRI or MDCT. 2. Change from baseline to follow-up plaque density and area of plaque detected by MDCT. 3. Correlation between change in plaque signal intensity detected by MRI and change in plaque density or plaque volume detected by MDCT. 4. Correlation between change in plaque signal intensity detected by MRI and change in blood biomarkers.